SCHEMBL15577798

SCHEMBL15577798

CCNCCNC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 2/20 0.67
KIF11 P52732 1/20 0.57
HTT P42858 2/20 0.40
DUT P33316 1/20 0.38
ADRB2 P07550 1/20 0.38
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
LMNA P02545 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
HTR1B P28222 1/20 0.34
HTR2A P28223 1/20 0.34
PRMT6 Q96LA8 1/20 0.34
TAAR1 Q96RJ0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29679194 0.87 KIF11 (0.65) KCNN4KIF11DUTMEN1KMT2A
SCHEMBL12264131 0.85 KIF11 (0.74) KCNN4KIF11DUTMEN1KMT2A
SCHEMBL8961063 0.81 KCNN4 (0.68) KCNN4KIF11HTTDUTKMT2A
SCHEMBL2490805 0.81 KCNN4 (1.00) KCNN4KIF11DUTTAAR1
SCHEMBL6251086 0.80 KIF11 (0.57) KCNN4KIF11DUT
SCHEMBL5675883 0.79 KIF11 (0.61) KCNN4KIF11HTTDUTMEN1
SCHEMBL9617559 0.78 KIF11 (0.78) KCNN4KIF11DUTMEN1KMT2A
SCHEMBL3626482 0.78 MEN1 (0.65) KCNN4KIF11MEN1KMT2ATDP1
SCHEMBL14288491 0.78 KCNN4 (0.63) KCNN4KIF11HTTDUTLMNA
SCHEMBL12264133 0.76 KIF11 (0.68) KCNN4KIF11DUTTAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2895457-B1 OLIGOMER-CONTAINING BENZAMIDE-BASED COMPOUNDS NEKTAR THERAPEUTICS (US) 2020-05-20 EP disclosed
US-10434181-B2 Oligomer-containing benzamide-based compounds NEKTAR THERAPEUTICS (US) 2019-10-08 US disclosed
US-20180185499-A1 OLIGOMER-CONTAINING BENZAMIDE-BASED COMPOUNDS NEKTAR THERAPEUTICS 2018-07-05 US disclosed
US-9937266-B2 Oligomer-containing benzamide-based compounds NEKTAR THERAPEUTICS (US) 2018-04-10 US disclosed
US-20160339108-A1 OLIGOMER-CONTAINING BENZAMIDE-BASED COMPOUNDS NEKTAR THERAPEUTICS 2016-11-24 US disclosed
US-9375486-B2 Oligomer-containing benzamide-based compounds NEKTAR THERAPEUTICS (US) 2016-06-28 US disclosed
US-20150250894-A1 Oligomer-Containing Benzamide-Based Compounds NEKTAR THERAPEUTICS (US) 2015-09-10 US disclosed
EP-2895457-A1 OLIGOMER-CONTAINING BENZAMIDE-BASED COMPOUNDS Nektar Therapeutics (US) 2015-07-22 EP disclosed
WO-2014043707-A1 OLIGOMER-CONTAINING BENZAMIDE-BASED COMPOUNDS NEKTAR THERAPEUTICS (US) 2014-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10434181-B2 Oligomer-containing benzamide-based compounds BRDT, BIRC5, BRD8 KCNN4 1400/4885KIF11 2521/4885HTT 15/4885
US-20160339108-A1 OLIGOMER-CONTAINING BENZAMIDE-BASED COMPOUNDS BRDT, BIRC5, BRD8 KCNN4 1400/4885KIF11 2521/4885HTT 15/4885
US-20150250894-A1 Oligomer-Containing Benzamide-Based Compounds BIRC5, BRDT, TBCB KCNN4 1448/4885KIF11 2566/4885HTT 15/4885
US-20180185499-A1 OLIGOMER-CONTAINING BENZAMIDE-BASED COMPOUNDS BRDT, BIRC5, BRD8 KCNN4 1400/4885KIF11 2521/4885HTT 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.